Why Guardant Health, Inc. (GH) stock moved
Guardant Health, Inc. (GH) shares tumbled 5.0% to $148.07 as of July 21, 2026, a significant decline from the prior close of $155.87. BestStocks flagged the session as a major change for GH. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for GH, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
GH fell 5.0% to $148.07
GH tumbled 5.0% in its latest session, moving from $155.87 to $148.07.
What it means for Guardant Health, Inc. investors
For Guardant Health, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Guardant Health, Inc. (GH) moved +5.07% from $156.17 to $164.08 on 2026-07-09; UnitedHealth Group announced coverage of Guardant Health's Shield blood test for colorectal cancer screening, expanding reimbursement access for the company's flagship screening product. Weighing against that: Sharp 5.0% decline — elevated risk; GH moved -4.14% from $162.92 to $156.17 on 2026-07-08. Wall Street's consensus price target sits at $163.73, implying +10.6% upside from $148.07. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 9 days out, the next report is the most likely near-term test of the move.
GH price reaction
GH last traded at $148.07, down $7.80 (-5.00%) from the previous close of $155.87. The session traded on 0.9× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $128.83 and $170.77, and it currently sits about 46% of the way up that band.
Bullish and bearish analyst opinions on Guardant Health, Inc. (GH)
The consensus analyst price target on Guardant Health, Inc. (GH) is $163.73, 10.6% above the recent $148.07. Over the past 90 days analysts logged 1 upgrade, 17 maintains, and 0 downgrades. Here is how the bullish and bearish cases on GH line up.
The bullish case
- Wall Street's consensus price target of $163.73 implies +10.6% upside from $148.07.
- The Street's most bullish target is $205.00 (+38.4%).
- 1 analyst upgrade in the past 90 days, most recently Evercore ISI Group to Outperform (2026-06-02).
- Guardant Health, Inc. (GH) moved +5.07% from $156.17 to $164.08 on 2026-07-09.
- UnitedHealth Group announced coverage of Guardant Health's Shield blood test for colorectal cancer screening, expanding reimbursement access for the company's flagship screening product.
The bearish case
- The most bearish analyst target is $115.00 (-22.3%).
- Sharp 5.0% decline — elevated risk.
- GH moved -4.14% from $162.92 to $156.17 on 2026-07-08.
- GH moved -3.49% from $168.82 to $162.92 on 2026-07-07.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for GH
Frequently asked questions about GH
Why did Guardant Health, Inc. (GH) stock move?
GH tumbled 5.0% to $148.07. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did GH stock fall?
GH lost 5.00% ($7.80) versus the prior close of $155.87, last trading at $148.07 on 0.9× average volume.
When is Guardant Health, Inc.'s next earnings date?
GH's next earnings report is estimated for 2026-07-30 — about 9 days away.
What is the analyst price target for GH?
The consensus analyst price target for GH is $163.73, about 10.6% above the current $148.07. Over the past 90 days, analysts recorded 1 upgrade, 17 maintains, and 0 downgrades.
How BestStocks tracks GH
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared GH-specific materiality thresholds, triggering an evidence check. It draws on 9 tracked change events for GH, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.